



## **Quanta to Attend the German Society of Nephrology 9th Annual Congress 2017**

**Alcester, Warwickshire, UK, 13 September 2017:** Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company will be attending the German Society of Nephrology 9th Annual Congress 2017 (DGFN 2017) taking place from Thursday 14th to Sunday 17th September 2017 at the Congress Center Rosengarten in Mannheim, Germany.

If you would like to arrange a meeting or product demonstration with Peter Hoyer, Chief Commercial Officer, at the conference, please contact [enquiries@quantadt.com](mailto:enquiries@quantadt.com).

**-ENDS-**

**For more information about Quanta, please contact:**

### **Quanta**

John E. Milad,  
Chief Executive Officer

T: +44 (0)1789 400043  
E: [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

### **Consilium Strategic Communications**

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708  
E: [quanta@consilium-comms.com](mailto:quanta@consilium-comms.com)

### **About SC+**

SC+ is a unique high performance, easy-to-use, compact haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates comparable to larger, conventional devices and is compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a leading edge design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. This cartridge-based design is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE mark) and is currently being used to treat patients in the UK.

### **About Quanta**

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by providing them with greater flexibility, convenience and control over the delivery of their life sustaining renal replacement therapy. Quanta is based in Alcester, UK and was founded in 2008. The company has attracted funding from a group of leading investors including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.

For more information, please visit: [www.quantadt.com](http://www.quantadt.com)